Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(5 sites)
United States
University Of Iowa, Iowa City, Iowa Massachusetts General Hospital, Boston, Massachusetts Corewell Health William Beaum Hosp, Royal Oak, Michigan Canada
Novartis Investigative Site, Montreal, Quebec South Korea
Novartis Investigative Site, Seoul, Korea